← Leaderboards
Jeffrey Meshulam
Profectus Biosciences, Inc.
$8,313,876
Attributed
$8,313,876
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7M · FY2016–19$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
Funding mix
By agency
NIH$8,313,876 · 2
By mechanism
N01$8,313,876 · 2
Top collaborators
No co-investigators on record.
Most similar at Profectus Biosciences, Inc.
Same institution · by research overlap
- Kenneth C Bagley$17,138,207
- John Eldridge$18,510,919
- Rong Xu$139,009
- Antony Dimitrov$5,981,560
- Jennifer A Schwartz$1,299,921
Others in their field
Top investigators on “Vaccine Candidate”
- Lawrence Corey · Fred Hutchinson Cancer Center$483,977,044
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$427,604,905
- Barton F Haynes · Duke University$290,267,445
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Peter B. Gilbert · Fred Hutchinson Cancer Center$195,104,733
- Wafaa M. El-Sadr · Columbia University Health Sciences$186,594,706
Research focus
Vaccine CandidateResearch Clinical TestingVaccinesLassa FeverAdvanced DevelopmentContractsCyclic GmpEbola VirusFilovirusFrankfurt-Marburg Syndrome VirusFreeze DryingPathogenPreparationVaccine DevelopmentUnited States National Institutes Of HealthHiv-1Hiv VaccineAcquired Immunodeficiency SyndromeNational Institute Of Allergy And Infectious DiseaseNonhuman PrimateAnimal ModelPhase I Clinical TrialsPre-ClinicalAids/Hiv Problem
Grant awards (3)
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$1,274,067
N01 · FY2019 · AI · contact PI
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever$6,964,520
N01 · FY2017 · AI · contact PI
IGF::OT::IGF PRODUCTION OF PDNA VACCINE EXPRESSING FLSC$75,289
N01 · FY2016 · AI · contact PI